Short answer
Candel Therapeutics, Inc. (CADL) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026.
Q3 2026 key financials · XBRL
- Net income
- −$22M
- −94.1% YoY · +43.8% QoQ
- EPS (diluted)
- −$0.28
- −27.3% YoY · +50.0% QoQ
Source: XBRL data from the Candel Therapeutics, Inc. (CADL) Q3 2026 10-Q on SEC EDGAR. USD.
Candel Therapeutics, Inc. Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $0, unchanged YoY, no product sales generated
- Net loss $21.9M vs $11.3M YoY, operating expenses $23.0M vs $13.2M
- R&D highest spending line: $15.6M vs $8.5M, driven by aglatimagene development
- Cash and equivalents $203.1M, operating cash use $58.3M, financing cash inflow $142.6M
- Outlook: cash runway into Q2 2028, additional capital required for NSCLC phase 3 and commercialization preparation
Risk Factors
- Newly added regulatory risk: June 2026 FDA guidance may require additional clinical data despite a single-trial approval pathway
- Most material financial update: $203.1 million cash expected to fund operations into Q2 2028
- Debt risk: Trinity facility totals $130.0 million, with $50.0 million outstanding and covenant-triggered acceleration possible
- Near-term operational risk: Small eligible brain-cancer population may delay linoserpaturev trial enrollment
- Compliance risk: GDPR violations may trigger fines up to €20 million or 4% of annual global revenues
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Candel Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.